Richard MortimerAlan WhiteChristian Frois
Although data on long-term cost-effectiveness of biologics are lacking, the expectation is that they will be cost-effective in the long-term. The idea behind this is that biologic treatment should be administered to patients that without these drugs would incur high direct and indirect costs due...
Cost analysis of biologic drugs in rheumatoid arthritis first line treatment after methotrexate failure according to patients' body weight The objective was to assess the influence of patients' weight in the cost of rheumatoid arthritis treatment with biologic drugs used in first line after no... JA...
For complex biologic products, such as insulin, it is impossible to make the identical product15. The term “biosimilars” is used (instead of “generics”) for products that are almost identical in composition, pharmacologic properties, and clinical effects. Biosimilar approval process is more cumb...
Facile genetic transfection of target cell populations is an indispensable aspect of modern molecular biology, involving the introduction of DNA/RNA substituents or other cell impermeable reagents (biologic drugs, peptides, etc.) to alter signaling responses of target cells1,2. Often, this results in...
Soini E. Biologisten lääkkeiden kustannusvaikuttavuus nivelpsoriaasin hoidossa [Cost-effectiveness of biologic drugs in the treatment of psoriatic arthritis]. Suomalaisen Lääkäriseuran Duodecimin ja Suomen Ihotautilääkäriyhdistyksen asettama tyoryhmä [Working group of Finnish...
but were na茂ve to tumor necrosis factor antagonists (i.e., biologic drugs).Cost-effectiveness analysis using a hybrid model structure (decision tree and Markov model) MEASUREMENTS AND MAIN RESULTS: A decision tree simulated biologic induction, and a Markov model simulated biologic and conventional...
A:Yes. Certain types of patients are prone to frequent acute exacerbations. If they continue to have recurrent episodes despite adequate treatment, they should be considered for treatment with a biologic, including Dupixent. Q: Asthma is categorized into allergic and eosinophilic, and biologics are ...
In the rebate negotiations between drugmakers and PBMs, the PBMs hold a high card. On behalf of their insurer clients, they create formularies—lists of drugs categorized according to how generously the insurer will cover a drug’s cost for beneficiaries. Every drugmaker wants its drugs in a...
Wailoo AJ, Bansback N, Brennan A, Michaud K, Nixon RM, Wolfe F (2008) Biologic drugs for rheumatoid arthritis in the medicare program: a cost-effectiveness analysis. Arthr Rheum 58(4):939–946 Article Google Scholar McIntosh E, Barlow J, Davis H, Stewart-Brown S (2009) Economic evalu...